Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	1.12B
Revenue (ttm)	16.00M
Net Income (ttm)	-297.06M
Shares Out	85.36M
EPS (ttm)	-3.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,322,787
Open	12.78
Previous Close	12.85
Day's Range	12.76 - 13.15
52-Week Range	12.76 - 25.34
Beta	0.84
Analysts	Strong Buy
Price Target	37.64 (+187.77%)
Earnings Date	Nov 5, 2024

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX
• Website: https://www.syndax.com

Analyst Forecast

According to 11 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $37.64, which is an increase of 187.77% from the latest price.

Price Target

$37.64

(187.77% upside)

Analyst Consensus: Strong Buy